Sunil Talathi of @BeOneMedicines sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company, prompt engineering, and the need for collaboration between humans and AI systems.

.@BioUsawa and @ServareGMP announced a strategic partnership to establish advanced monoclonal antibody manufacturing capabilities in Africa, directly addressing the critical healthcare access gap affecting patients in low- and middle-income countries.

Arun Upadhyay @Ocugen discusses inherited retinal diseases, the company’s gene therapies that can work across different genetic mutations, and the potential of its platform technology beyond the eye. @GlobalGenes #RARECast.

Jenny Marlowe and Melissa Bonner of @nchromabio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies.

Steve Mahoney @ViridianThera discusses thyroid eye disease, the challenges of living with the condition, and why its veligrotug has the potential to provide a new alternative for people living with the condition. @GlobalGenes #RARECast.

.@CraigLipset, advisor and founder of Clinical Innovation Partners, discusses how AI can bring greater predictability to clinical trials, how organizations can effectively adopt the technology, and the importance of fostering a culture of experimentation.

.@Niven_Narain , CEO of BPGbio discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic.

Traci Davies and her son Ben Davies both discuss their experiences with primary immunodeficiency, what it’s like to be both a caregiver and patient, and why they have both become patient advocates. @GlobalGenes #RARECast.

.@PunitDhillon @skyebioscience discusses the limits of GLP-1 obesity therapies, the company’s experimental obesity therapy that works on a different target, and the potential to combine it with GLP-1 agonists and other therapeutic approaches.

Here's what you may have missed in June from The Bio Report, RARECast, and the Life Sciences D'n'A podcasts.

Bio Usawa and Bioeq AG announce a groundbreaking agreement to bring a life-changing biosimilar medicine—ranibizumab, used to treat serious retinal diseases—within reach for millions across Sub-Saharan Africa.

Melanie Kandzierski discusses how she has learned to care for a child with Dravet syndrome, care for herself, and to advocate not only for her child but others with complex medical conditions. @GlobalGenes #RARECast.

Ariel Katz @H1co_ discusses the unique dataset behind the company’s platform to connect life sciences companies to healthcare providers, the problem it solves for biopharmaceutical companies, and some unexpected ways the platform has been used.

Steve Ruston, CEO of Persica Pharmaceuticals, discusses the need for new approaches to chronic low back pain, the company’s experimental targeted antibiotic injections, and the need to educate physicians about the role infection can play in the condition.

Patrick Ritschel of Atsena Tx discusses the delivery challenges of gene therapies for inherited retinal diseases, how the company’s vector technology addresses this, and how it allows for safer and more effective delivery. @GlobalGenes #RARECast.

Barry Quart @ConnectBiopharm discusses the unmet need in asthma and COPD, the company’s experimental therapy rademikibart, and the case for a biologic that can address acute exacerbations of these conditions.

P.J. Brooks of @NIH @ncats_nih_gov discusses the treatment of an infant with a bespoke gene editing therapy, how researchers were able to move from diagnosis to treatment with speed, and what it would take to scale such an approach. @globalgenes #RARECast.

Venky Iyer, director of data strategy and automation at @pfizer, discusses his journey in implementing AI solutions to enhance operational efficiency, the importance of managing change, and the value of AI adoption in improving drug development processes.

LeelandEkstrom of @NashvilleBio discusses its founding as a for-profit subsidiary of @VUMCDiscoveries, the significance its alliance with leading biopharmaceutical companies, and how it's enabling a transformation of drug development with data.

Annette Bakker @ChildrensTumor discusses the complexities of neurofibromatosis, the foundation’s role in advancing research and drug development, and what other patient organizations can learn from its strategic approach.